Expression and prognostic value of EGFR in invasive breast cancer

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1655-1663

  Quintela, I ^a   Corte, M D ^b   Allende, M T ^b,c   Vazquez, J ^a,b   Rodriguez, J C ^a,b   Bongera, M ^a   Lamelas, M ^a,b   Gonzalez, L O ^a,b   Vega, A ^b   Garcia Muniz J L ^c   Astudillo, A ^b,c   Vizoso, F ^a,b  

^a HOSPITAL DE JOVE   (Spain)

^b DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Breast cancer; Prognosis; Tyrosine kinase receptor

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST TUMOR; CANCER INVASION; ENZYME IMMUNOASSAY; FEMALE; FLOW CYTOMETRY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; RADIOASSAY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM INVASIVENESS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOLIGAND ASSAY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL ANALYSIS;

EID: 33644675170     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1655     Document Type: Article

References (61)

1. Osborne CK and Arteaga CL: Autocrine and paracrine growth regulation of breast cancer: clinical implications. Breast Cancer Res Treat 15: 3-11, 1990. (Pubitemid 20139593)
2. Ullrich A and Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61: 203-212, 1990.
3. Alroy I and Yarden Y: The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410: 83-86, 1997. (Pubitemid 27283389)
4. Klapper LN, Kirschbaum MH, Sela M and Yarden Y: Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79, 2000. (Pubitemid 29439302)
5. Lemmon MA and Schlessinger J: Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 19: 459-463, 1994. (Pubitemid 24342757)
6. Gullick WJ and Srinivasan R: The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 52: 43-53, 1998. (Pubitemid 29056084)
7. Downward J, Waterfield MD and Parker PJ: Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem 260: 14538-14546, 1985. (Pubitemid 16210976)
8. Xu YH, Ishii S, Clark AJ, Sullivan M, Wilson RK, Ma DP, et al: Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature 309: 806-810, 1984. (Pubitemid 14119435)
9. Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I, et al: Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 238: 1408-1410, 1987. (Pubitemid 18015962)
10. Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson S A, et al: Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 4: 831-838, 1989. (Pubitemid 19176969)
11. Woodburn JR: The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 82: 241-250, 1999.
12. Kim ES, Khuri FR and Herbst RS: Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13: 506-513, 2001. (Pubitemid 33027904)
13. Heldin CH and Westermark B: Growth factors: mechanism of action and relation to oncogenes. Cell 37: 9-20, 1984. (Pubitemid 14079832)
14. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG and Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13: 565-569, 1993.
15. Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song MM, et al: Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 17: 3841-3847, 1997. (Pubitemid 28014948)
16. Umekita Y, Ohi Y, Sagara Y and Yoshida H: Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 89: 484-487, 2000.
17. Arteaga CL: The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19: S32-S40, 2001.
18. Sainsbury JR, Farndon JR, Needham GK, Malcolm A J and Harris AL: Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet i: 1398-1402, 1987. (Pubitemid 17078859)
19. Spyratos F, Delarue JC, Andrieu C, Lidereau R, Champeme MH, Hacene K, et al: Epidermal growth factor receptors and prognosis in primary breast cancer. Breast Cancer Res Treat 17: 83-89, 1990.
20. Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, et al: Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49: 7002-7009, 1989. (Pubitemid 20016583)
21. Seshadri R, McLeay WR, Horsfall DJ and McCaul K: Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer. Int J Cancer 69: 23-27, 1996. (Pubitemid 26083266)
22. Lewis S, Locker A, Todd JH, Bell JA, Nicholson R, Elston CW, et al: Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43: 385-389, 1990. (Pubitemid 20154199)
23. Toi M, Tominaga T, Osaki A and Toge T: Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study. Breast Cancer Res Treat 29: 51-58, 1994. (Pubitemid 24104837)
24. Tsutsui S, Kataoka A, Ohno S, Murakami S, Kinoshita J and Hachitanda Y: Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8: 3454-3460, 2002. (Pubitemid 35340721)
25. Pilichowska M, Kimura N, Fujiwara H and Nagura H: Immunohistochemical study of TGF-alpha, TGF-betal, EGFR, and IGF-1 expression in human breast carcinoma. Mod Pathol 10: 969-975, 1997. (Pubitemid 27471116)
26. Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, et al: Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer 65: 1980-1984, 1990. (Pubitemid 20147637)
27. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J and Nicholson R: Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. Br J Cancer 69: 1032-1037, 1994. (Pubitemid 24161855)
28. Klijn JG, Look MP, Portengen H, Alexieva-Figusch J, van Putten WL and Foekens JA: The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 29: 73-83, 1994. (Pubitemid 24104839)
29. Nicholson S, Richard J, Sainsbury C, Halcrow P, Kelly P, Angus B, et al: Epidermal growth factor receptor (EGFr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup. Br J Cancer 63: 146-150, 1991.
30. Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D and Harris AL: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29: 41-49, 1994. (Pubitemid 24104836)
31. Torregrosa D, Bolufer P, Lluch A, Lopez JA, Barragan E, Ruiz A, et al: Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin Chim Acta 262: 99-119, 1997. (Pubitemid 27241382)
32. Newby JC, Johnston SR, Smith IE and Dowsett M: Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3: 1643-1651, 1997. (Pubitemid 27431575)
33. Nicholson S, Sainsbury JR, Halcrow P, Chambers P, Farndon JR and Harris AL: Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet i: 182-185, 1989. (Pubitemid 19038803)
34. Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blarney RW, et al: Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 72: 1259-1266, 1995.
35. Klijn JG, Berns PM, van Putten WL, Bontenbal M, Alexieva-Figusch J and Foekens JA: Critical review of growth factors as clinical tools in primary and metastatic breast cancer. Recent Results Cancer Res 127: 77-88, 1993.
36. Bloom HJ and Richardson WW: Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359-377, 1957.
37. Hedley DW, Shankey TV and Wheeless LL: DNA cytometry consensus conference. Cytometry 14: 471, 1993. (Pubitemid 23191953)
38. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
39. Marchalonis JJ: An enzymic method for the trace iodination of immunoglobulins and other proteins. Biochem J 113: 299-305, 1969.
40. Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, et al: Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Res Treat 17: 211-219, 1991.
41. Ferrero JM, Ramaioli A, Largillier R, Formento JL, Francoual M, Ettore F, et al: Epidermal growth factor receptor expression in 780 breast cancer patients: a reappraisal of the prognostic value based on an eight-year median follow-up. Ann Oncol 12: 841-846, 2001. (Pubitemid 32655096)
42. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227-238, 1998.
43. Tsutsui S, Ohno S, Murakami S, Hachitanda Y and Oda S: Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 71: 67-75, 2002. (Pubitemid 34121818)
44. Mulero M, Fernandez Raigoso P, Vazquez J, Lamelas ML, Corte D, Allende MT, et al: [Clinical significance of tumor content of epidermal growth factor receptor in breast cancer]. Rev Esp Med Nucl 22: 386-394, 2003.
45. Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, et al: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91: 1532-1542, 2004.
46. Davidson NE, Gelmann EP, Lippman ME and Dickson RB: Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223, 1987.
47. Nicholson RI and Gee JM: Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 82: 501-513, 2000. (Pubitemid 30085181)
48. Van Agthoven T, van Agthoven TL, Portengen H, Foekens JA and Dorssers LC: Ectopic expression of epidermal growth factor receptors induces hormone independence in ZR-75-1 human breast cancer cells. Cancer Res 52: 5082-5088, 1992.
49. Suo Z, Emilsen E, Tveit KM and Nesland JM: Type 1 protein tyrosine kinases in benign and malignant breast lesions. Histopathology 33: 514-521, 1998. (Pubitemid 28563376)
50. Bevilacqua P, Gasparini G, Dal Fior S and Corradi G: Immunocytochemical determination of epidermal growth factor receptor with monoclonal EGFR1 antibody in primary breast cancer patients. Oncology 47: 313-317, 1990. (Pubitemid 20226115)
51. Tovey SM, Witton CJ, Bartlett JM, Stanton PD, Reeves JR and Cooke TG: Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6: R246-R251, 2004.
52. Rampaul RS, Pinder SE, Wencyk PM, Nicholson RI, Blamey RW, Robertson JF, et al: Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value? Clin Cancer Res 10: 2578, 2004. (Pubitemid 38445721)
53. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, Robertson JF, et al: Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125, 1994. (Pubitemid 24104843)
54. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, et al: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10: 5670-5676, 2004. (Pubitemid 39180941)
55. Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB and Rose C: Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 19: 3376-3384, 2001. (Pubitemid 32642190)
56. De Placido S, De Laurentiis M, Carlomagno C, Gallo C, Perrone F, Pepe S, et al: Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 9: 1039-1046, 2003. (Pubitemid 36323709)
57. Dickstein BM, Wosikowski K and Bates SE: Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 110: 205-211, 1995.
58. Cantwell BM, Hennessy C, Millward MJ and Lennard TW: Epidermal growth factor receptors and doxorubicin plus ifosfamide/mesna in recurrent breast cancer. Lancet 337: 1417, 1991.
59. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J and Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1: 511-529, 1983.
60. Laskin JJ and Sandler AB: Epidermal growth factor receptor: a promising target in solid tumours. Cancer Treat Rev 30: 1-17, 2004. (Pubitemid 38240085)
61. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, et al: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196: 17-25, 2002.